Clinical Trial Update: A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Iressa (gefitinib) for breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN